Stereotactic arrhythmia radioablation and its implications for modern cardiac electrophysiology: results of an EHRA survey

• DOI: 10.1093/europace/euae110
• Publication Date: 2024-04-26T09:41:46Z
• Authors: Boldizsar Kovacs; Helge Immo Lehmann; Martin Manninger; Ardan Muammer Sag...; Piotr Futyma; David Duncker; Julian Chun
• Keywords: Electrophysiology study; Demographics

Stereotactic arrhythmia radioablation (STAR) is a treatment option for recurrent ventricular tachycardia/fibrillation (VT/VF) in patients with structural heart disease (SHD). The current and future role of STAR as viewed by cardiologists unknown. study aimed to assess the role, barriers application, expected STAR. An online survey consisting 20 questions on baseline demographics, awareness/access, use, was conducted. A total 129 international participants completed [mean age 43 ± 11 years, 25 (16.4%) female]. Ninety-one (59.9%) were electrophysiologists. Nine (7%) unaware therapeutic option. Sixty-four (49.6%) had access STAR, while 62 (48.1%) treated/referred patient treatment. Common primary indications VT/VF SHD (45%), without (7.8%), or premature contraction (3.9%). Reported main advantages efficacy arrhythmias not amenable conventional (49%) non-invasive approach overall low acute short-term procedural risk (23%). Most respondents have foreseen clinical underlying (72% 75%, respectively), although only minority first-line indication it (7% 5%, respectively). novel VT appears gain acceptance within cardiology community. Further trials are critical further define efficacy, populations, well appropriate use VT.